Omega Protein Corporation
Nov 17, 2014
PDF
Add to Briefcase

Omega Protein Announces Third Quarter 2014 Financial Results

HOUSTON, Nov. 17, 2014 /PRNewswire/ -- Omega Protein Corporation (NYSE: OME), a nutritional product company and a leading integrated provider of specialty oils, essential fatty acids and specialty protein products, today reported financial results for the third quarter ended September 30, 2014.

Omega Protein Corporation Logo.

Third Quarter Highlights

  • Revenues:  $70.8 million for the quarter, compared to $87.6 million in the same period a year ago
  • Gross profit margin:  20.0% for the quarter, compared to 33.6% in the same period a year ago
  • Net income: $0.7 million, or $1.7 million excluding plant closure charges and loss on disposal of assets for the quarter, compared to $14.0 million, in the same period a year ago
  • Earnings per diluted share: $0.03, or $0.08 excluding plant closure charges and loss on disposal of assets for the quarter, compared to $0.66 in the same period a year ago
  • Adjusted EBITDA:  $9.3 million for the quarter, compared to $27.1 million in the same period a year ago

"We remain focused on executing our strategic initiatives to drive long-term growth.  These initiatives include leveraging our recently strengthened human nutrition product portfolio with the acquisition of Bioriginal Food & Science Corp., as we further diversify and balance our business to take advantage of global health and wellness trends," commented Bret Scholtes, Omega Protein's President and Chief Executive Officer. "Our third quarter results reflect previously discussed declines in fish catch and fish oil yields compared to last year's exceptional season, which offset continued favorable pricing dynamics in our animal nutrition segment."

Third Quarter 2014 Results

The Company's revenues decreased 19% from $87.6 million in the same period last year to $70.8 million.  This decrease was due to a $24.7 million decline in animal nutrition revenues, partially offset by a $7.9 million increase in human nutrition revenues.  The decrease in animal nutrition revenues was primarily due to lower sales volumes of 28% and 41% for the Company's fish meal and fish oil, respectively, and lower sales prices for the Company's fish meal of 4%, partially offset by higher sales prices of 14% for the Company's fish oil.  The decrease in fish meal and fish oil sales volumes is primarily due to lower production as a result of decreased fish oil yields, slower than anticipated early season fish catch, and the previously announced Cameron plant closure. The increase in fish oil sales prices was primarily due to higher realized crude oil prices. The increase in human nutrition revenues was primarily attributable to the acquisition of Bioriginal Food & Science Corp. ("Bioriginal"), which was acquired on September 5, 2014. The composition of revenues by nutritional product line for the third quarter of 2014 was 49% fish meal, 27% fish oil, 22% dietary supplements and food, and 2% fish solubles and other. 

Third quarter of 2014 revenues decreased 2% from $71.9 million in the second quarter of 2014 to $70.8 million.  This decrease was due to lower animal nutrition revenues of $10.1 million, partially offset by higher human nutrition revenues of $9.0 million. The decrease in animal nutrition revenues was primarily due lower sales volumes of 37% and 8% for the Company's fish oil and fish meal, respectively, partially offset by higher sales prices of 14% and 1% for the Company's fish oil and fish meal, respectively. The increase in human nutrition revenues was primarily due to the acquisition of Bioriginal.

The Company reported gross profit of $14.2 million, or 20.0% as a percentage of revenues, for the third quarter of 2014, versus $29.4 million, or 33.6% as a percentage of revenues, in the third quarter of 2013. The decrease in gross profit as a percentage of revenues was due to reductions in both the animal and human nutrition segments.  Animal segment gross profit as a percentage of revenues declined from 34.5% to 25.8%, due primarily to a higher cost per unit for current season production.  Human nutrition gross profit as a percentage of revenues decreased from 24.6% to a gross loss of 0.1% due primarily to start-up costs associated with the Company's protein plant expansion, increased protein raw material costs and $0.8 million of additional expense associated with the acquisition-related write-up of Bioriginal's inventory to fair value.

Compared to the second quarter of 2014, third quarter gross profit decreased from $20.4 million, or 28.4% as a percentage of revenues, to $14.2 million, or 20.0% as a percentage of revenues.  Animal nutrition gross profit as a percentage of revenues decreased from 30.3% to 25.8%, primarily reflecting a higher cost per unit for current season production.  Human nutrition segment gross profit as a percentage of revenues decreased from 9.9% to a gross loss of 0.1% due largely to the start-up costs associated with the Company's protein plant expansion and Bioriginal's acquisition-related inventory write-up to fair value.

Selling, general and administrative expenses for the third quarter increased $3.3 million to $10.2 million compared to the third quarter of 2013, primarily due to $2.7 million of pretax professional expenses ($2.5 million after tax) related to the acquisition of Bioriginal.  Selling, general and administrative expenses increased $3.7 million from $6.5 million in the second quarter of 2014.

In the fourth quarter of 2013, the Company closed its menhaden fish processing plant located in Cameron, Louisiana and re-deployed certain vessels from that facility to the Company's other Gulf Coast facilities.  In conjunction with the closure, the Company incurred charges of $1.5 million in the third quarter of 2014. 

The third quarter of 2014 effective tax rate was 60.6% compared to 34.6% in the third quarter of 2013 and 36.9% in the second quarter of 2014. The increase in the effective tax rate was primarily a result of non-deductible expenses related to the acquisition of Bioriginal.  The effective tax rate in the third quarter would have been approximately 23.3% were it not for these expenses.

Net income for the third quarter of 2014 was $0.7 million ($0.03 per diluted share) compared to $14.0 million ($0.66 per diluted share) in the same period last year and $6.6 million ($0.31 per diluted share) for the second quarter of 2014. Excluding plant closure charges and gain or loss on disposal of assets, net income for the third quarter of 2014 would have been $1.7 million ($0.08 per diluted share), compared to $13.9 million ($0.65 per diluted share) in the same period last year and $8.3 million ($0.38 per diluted share) for the second quarter of 2014.  Net income for the third quarter of 2014 includes a net loss of $(0.3) million from Bioriginal.

Adjusted EBITDA totaled $9.3 million for the third quarter of 2014, compared to $27.1 million for the same period last year and $18.3 million for the second quarter of 2014.

Nine Month 2014 Results

Revenues in the first nine months of 2014 increased 16% to $206.2 million compared to revenues of $178.3 million for the nine months ended September 30, 2013. The increase in revenues was due to a $19.0 million increase in animal nutrition revenues and an $8.8 million increase in human nutrition revenues. The increase in animal nutrition revenues was primarily due to higher sales volumes of 49% for the Company's fish oil and higher sales prices of 2% for the Company's fish meal.  This was partially offset by lower sales volumes of 5% for the Company's fish meal and lower sales prices of 2% for the Company's fish oil. The increase in human nutrition revenues was due primarily to the acquisition of Bioriginal.

The Company recorded gross profit of $55.1 million, or 26.7% as a percentage of revenues, for the first nine months of 2014, versus gross profit of $54.8 million, or 30.7% as a percentage of revenues, for the first nine months of 2013.  The decrease in gross profit as a percentage of revenues was primarily due to the impact of decreased fish oil yields and slower than anticipated early season fish catch on cost per unit of sales as well as lower human nutrition gross profit as a percentage of revenues.

The effective tax rate was 37.0% for the nine months ended September 30, 2014 compared to 34.4% for the nine months ended September 30, 2013.  The effective tax rate for the nine months ended September 30, 2014 would have been approximately 34.4% were it not for the non-deductible expenses related to the acquisition of Bioriginal.

Net income for the nine months ended September 30, 2014 was $15.3 million ($0.70 per diluted share) compared to $20.8 million ($0.99 per diluted share) for the same period last year.  Excluding the impact of the plant closure and loss on disposal of assets, net income for the nine months ended September 30, 2014 would have been $19.0 million ($0.88 per diluted share) compared to $21.0 million ($1.00 per diluted share).

Adjusted EBITDA totaled $46.7 million for nine months ended September 30, 2014, a decrease from $48.9 million for the same period last year.

Balance Sheet

Due in large part to the Bioriginal acquisition, the Company's September 30, 2014 cash balance decreased $32.3 million from December 31, 2013 to $1.7 million, and total debt increased $30.7 million from December 31, 2013 to $54.9 million on September 30, 2014.  Stockholders' equity increased $19.5 million to $266.7 million as of September 30, 2014 compared to $247.2 million as of December 31, 2013

Conference Call Information

Omega Protein will host a conference call on its third quarter 2014 financial results at 8:30 a.m., Eastern Time, on Tuesday, November 18, 2014. The Company's senior management team will be available to discuss recent financial results and current business trends as well as respond to questions.

Please dial (877) 407-3982 domestically or (201) 493-6780 internationally to join the call. Interested parties may also listen to the webcast live over the Internet at www.omegaprotein.com.  

A webcast replay of the conference call will be available beginning shortly after the conclusion of the call at www.omegaprotein.com and will be available for 30 days. A telephonic replay of the conference call will be available through December 2, 2014. Domestic listeners can dial (877) 870-5176, and international listeners may dial (858) 384-5517. The replay access code is 13593645.

About Omega Protein

Omega Protein Corporation (NYSE:OME) is a century old nutritional product company that develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of foods, dietary supplements and animal feeds. Omega Protein's mission is to help people lead healthier lives with better nutrition through sustainably sourced ingredients such as highly-refined specialty oils and essential fatty acids, specialty protein products and nutraceuticals.

The Company operates eight manufacturing facilities located in the United States, Canada and Europe. The Company also operates more than 30 fishing vessels to harvest menhaden, a fish abundantly found off of the coasts of the Atlantic Ocean and Gulf of Mexico. For more information, please visit www.omegaprotein.com.

Forward Looking Statements

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: The statements contained in this press release that are not historical facts are forward-looking statements that involve a number of risks and uncertainties. Forward-looking information may be based on projections, predictions and estimates. Some statements in this press release may be forward-looking and use words like "may," "may not," "believes," "do not believe," "expects," "do not expect," "anticipates," "do not anticipate," "see," "do not see," "should," or other similar expressions. The actual results of future events described in any of these forward-looking statements could differ materially from those stated in the forward-looking statements. Important factors that could cause actual results to be materially different from those forward-looking statements include, among others: (1) the Company's ability to meet its raw material requirements through its annual menhaden harvest, which is subject to fluctuations due to natural conditions over which the Company has no control, such as varying fish population, fish oil yields, adverse weather conditions, natural and other disasters and disease; (2) the impact of laws and regulations that may be enacted that may restrict the Company's operations or the sale of the Company's products; (3) the impact of worldwide supply and demand relationships on prices for the Company's products; (4) the Company's expectations regarding demand and pricing for its products proving to be incorrect, and the effect of forward sales of products on the Company's financial results; (5) fluctuations in the Company's quarterly operating results due to the seasonality of the Company's business, estimates of standard cost for inventory and subsequent adjustments to such costs, and the Company's deferral of inventory sales based on worldwide prices for competing products; (6) the Company's ability to realize the anticipated benefits from its acquisitions in the human nutrition business, and specifically, to integrate successfully its recent acquisition of Bioriginal; (7) the Company's expectations regarding Nutegrity or Bioriginal, their future prospects and the dietary supplement market or the human health and wellness segment generally, proving to be incorrect; (8) the cost of compliance with existing and future government regulations; (9) the impact of the Company's settlement with U.S. Attorney's Office on the Company's operations and financial results, including the impact of any failure to comply with the terms of the Company's probation or the limitations imposed on the Company's ability to secure government contracts or loans under the NFMS Title XI program; (10) the impact of the closure of the Company's Cameron, Louisiana processing plant on the Company's operations and financial results; and (11) the cost of compliance or potential restrictions on sales caused by laws and regulations regarding fish meal or oil importation into foreign jurisdictions.  Other factors are described in further detail in the Company's filings with the Securities and Exchange Commission, including its reports on Form 10-K, Form 10-Q and Form 8-K.

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

(Dollars in thousands)



September 30,

2014


December 31,

2013

ASSETS






 Current assets:






          Cash and cash equivalents

$

1,714


$

34,059

          Receivables, net


46,099



21,140

          Inventories


107,919



94,339

          Deferred tax asset, net


1,772



1,062

          Prepaid expenses and other current assets


5,911



3,915

                Total current assets


163,415



154,515

Other assets, net


2,666



5,234

Property, plant and equipment, net


165,529



144,113

Goodwill


50,658



19,600

Other intangible assets, net


21,388



7,932

                Total assets

$

403,656


$

331,394







LIABILITIES AND STOCKHOLDERS' EQUITY












Current liabilities:






         Current maturities of long-term debt

$

14,157


$

3,112

         Accounts payable


14,893



5,380

         Accrued liabilities


38,448



29,145

              Total current liabilities


67,498



37,637

Long-term debt, net of current maturities


40,770



21,130

Deferred tax liability, net


23,773



19,351

Pension liabilities, net


2,516



4,117

Other long-term liabilities


2,414



1,929

                Total liabilities


136,971



84,164

Commitments and contingencies






Stockholders' equity:






        Preferred stock, $0.01 par value; 10,000,000 authorized shares; none issued                                    




        Common Stock, $0.01 par value; 80,000,000 authorized shares;

          21,587,751 and 20,804,189 shares issued and 21,578,733 and

          20,804,189 shares outstanding at September 30, 2014 and

          December 31, 2013, respectively


 

208



 

 

203

        Capital in excess of par value


141,153



136,428

        Retained earnings


132,070



116,807

        Treasury stock, at cost - 9,018 shares


(119)



        Accumulated other comprehensive loss


(6,627)



(6,208)

                Total stockholders' equity


266,685



247,230

                    Total liabilities and stockholders' equity

$

403,656


$

331,394







 

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(In thousands, except per share amounts)




Three Months Ended


Nine Months Ended



September 30,


September 30,



2014


2013


2014


2013

Revenues

$

70,764

$

87,620

$

206,177

$

178,320

Cost of sales


56,586


58,200


151,082


123,520

Gross profit


14,178


29,420


55,095


54,800










Selling, general, and administrative expense


10,216


6,930


22,835


19,403

Research and development expense


608


650


1,636


1,770

Impairment of intangible assets



80



80

Loss related to plant closure


1,543



5,482


Loss (gain) on disposal of assets


12


(161)


245


213

Operating income


1,799


21,921


24,897


33,334

Interest income


4


5


17


15

Interest expense


(365)


(483)


(747)


(1,356)

Gain on foreign currency


272



272


Other expense, net


(39)


(104)


(213)


(285)

Income before income taxes


1,671


21,339


24,226


31,708










Provision for income taxes


1,012


7,377


8,963


10,911

Net income


659


13,962


15,263


20,797










Other comprehensive income (loss):









Foreign currency translation adjustment net of tax benefit of $243, $0, $243 and $0, respectively


(449)



(449)


Energy swap adjustment, net of tax (expense) benefit of $204, ($54), $224 and $2, respectively


(379)


101


(416)


(5)

Pension benefits adjustment, net of tax expense of $80, $135, $240 and $405, respectively


149


251


446


753

Comprehensive income (loss)

$

(20)

$

14,314

$

14,844

$

21,545

Basic earnings per share

$

0.03

$

0.68

$

0.73

$

1.03

Weighted average common shares outstanding


20,637


20,150


20,474


19,801

 

Diluted earnings per share

 

$

 

0.03

 

$

 

0.66

 

$

 

0.70

$

 

0.99

Weighted average common shares and potential

  common share equivalents outstanding


 

21,258


 

20,762


 

21,122


 

20,520

 

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(Dollars in thousands)




Nine Months Ended

September 30,



2014


2013

Cash flows from operating activities:





       Net income

$

15,263

$

20,797

       Adjustments to reconcile net income to net cash provided by operating activities:





        Depreciation and amortization


16,072


15,627

        Loss on plant closure


2,055


        Loss (gain) on disposal of assets


245


213

        Impairment of intangible assets



80

        Provisions for losses on receivables


36


36

        Share based compensation


1,688


1,461

        Deferred income taxes


(936)


5,074

        Unrealized (gain) on foreign currency fluctuations, net


(272)


        Changes in assets and liabilities:





                 Receivables


(9,861)


(604)

                 Inventories


6,331


(22,700)

                 Prepaid expenses and other current assets


(602)


(1,782)

                 Other assets


1,454


5,409

                 Accounts payable


(1,880)


938

                 Accrued liabilities


9,030


2,538

                 Pension liability, net


(1,063)


(622)

                 Other long term liabilities


(21)


182

                         Net cash provided by operating activities


37,539


26,647

Cash flows from investing activities:





        Proceeds from disposition of assets


257


313

        Acquisition of Wisconsin Specialty Protein, net of cash acquired



(26,676)

        Acquisition of Bioriginal, net of cash acquired


(46,388)


        Land and building purchased in capital lease extinguishment



(5,005)

        Capital expenditures


(36,254)


(18,009)

                         Net cash used in investing activities


(82,385)


(49,377)

Cash flows from financing activities:





        Principal payments of long-term debt


(14,776)


(2,316)

        Proceeds from long-term debt


24,000


        Principal payments of capital lease obligation



(309)

        Purchase treasury stock at cost


(119)


        Proceeds from stock options exercised


2,245


3,048

        Excess tax benefit of stock options exercised


1,151


1,147

                         Net cash provided by (used in) financing activities


12,501


1,570

Net increase (decrease) in cash and cash equivalents


(32,345)


(21,160)

Cash and cash equivalents at beginning of year


34,059


55,998

Cash and cash equivalents at end of period

$

1,714

$

34,838

 

The tables below present information about reported segments for three months ended September 30, 2014 and 2013 (in thousands).  It should be noted that all cash and cash equivalent balances have been included in the identifiable assets of the unallocated segment.   

September 30, 2014


Animal
Nutrition


Human
Nutrition
(1)


Unallocated


Total

Revenues (2)         


$  55,123


$   15,641


  $           ―


$  70,764

Cost of sales        


40,920


15,666


            ―


56,586

Gross profit          


14,203


(25)


            ―


14,178

Selling, general and administrative expenses

  (including research and development)          


540


2,985


7,299


10,824

Loss related to plant closure             


1,543


          ―


              ―


1,543

Other (gains) and losses    


12


          ―


              ―


12

Operating income (loss)     


$   12,108


$  (3,010)


$    (7,299)


$     1,799

Depreciation and amortization          


$     4,332


$    1,136


$         269


$     5,737

Identifiable assets               


$ 233,239


$167,838


$      2,579


$ 403,656

Capital expenditures           


$     4,179


$    7,884


$         923


$   12,986



(1)

Includes revenues and related expenses for Bioriginal from September 5, 2014 through September 30, 2014.

(2)

Excludes revenues from internal customers of $0.4 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

 

September 30, 2013


Animal Nutrition


Human Nutrition


Unallocated


Total

Revenues (3)         


$   79,828


$    7,792


  $            ―


$   87,620

Cost of sales        


52,321


5,879


             ―


58,200

Gross profit          


27,507


1,913


             ―


29,420

Selling, general and administrative expenses

  (including research and development)          


733


1,924


4,923


7,580

Other (gains) and losses    


(160)


79


              ―


(81)

Operating income (loss)     


$  26,934


$       (90)


$    (4,923)


$   21,921

Depreciation and amortization          


$     4,531


$       651


$        192


$    5,374

Identifiable assets               


$ 271,363


$  54,095


$     1,323


$326,781

Capital expenditures           


$     3,960


$    1,062


$          90


$     5,112



(3)

Excludes revenues from internal customers of $0.3 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

 

The tables below present information about reported segments for the nine months ended September 30, 2014 and 2013 (in thousands).

September 30, 2014


Animal
Nutrition


Human
Nutrition
(4)


Unallocated


Total

Revenues (5)         


$ 175,657


$  30,520


  $           ―


$ 206,177

Cost of sales        


122,588


28,494


             ―


151,082

Gross profit          


53,069


2,026


             ―


55,095

Selling, general and administrative expenses

  (including research and development)          


1,729


6,973


15,769


24,471

Loss related to plant closure             


5,482


           ―


              ―


5,482

Other (gains) and losses    


54


191


              ―


245

Operating income (loss)     


$  45,804


$  (5,138)


$ (15,769)


$    24,897

Depreciation and amortization          


$  13,074


$    2,536


$        462


$    16,072

Identifiable assets               


$233,239


$167,838


$     2,579


$ 403,656

Capital expenditures           


$  14,537


$  20,785


$        932


$   36,254



(4)

Includes revenues and related expenses for Bioriginal from September 5, 2014 through September 30, 2014.

(5)

Excludes revenues from internal customers of $1.8 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

 

September 30, 2013


Animal Nutrition


Human
Nutrition
(6)


Unallocated


Total

Revenues (7)         


$  156,618


$   21,702


  $            ―


$   178,320

Cost of sales        


106,201


17,319


             ―


123,520

Gross profit          


50,417


4,383


             ―


54,800

Selling, general and administrative expenses

  (including research and development)          


2,023


5,081


14,069


21,173

Other (gains) and losses    


214


79


             ―


293

Operating income (loss)     


$    48,180


$      (777)


$    (14,069)


$     33,334

Depreciation and amortization          


$    13,352


$    1,721


$          554


$     15,627

Identifiable assets               


$  271,363


$  54,095


$       1,323


$  326,781

Capital expenditures           


$    16,006


$    1,675


$          328


$    18,009



(6)

Includes revenues and related expenses for WSP from February 27, 2013 through September 30, 2013.

(7)

Excludes revenues from internal customers of $1.3 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

 

Adjusted EBITDA to Net Income Reconciliation
The following table (in thousands) provides a reconciliation of Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended September 30, 2014, June 30, 2014 and September 30, 2013 and the nine months ended September 30, 2014 and September 30, 2013:




 Three Months Ended



September 30,

 2014


June 30,

 2014


September 30,

 2013

Net Income

$

659

$

6,633

$

13,962

Reconciling items:







   Interest expense


334


105


452

   Income tax provision


1,012


3,871


7,377

   Depreciation and amortization


5,737


5,118


5,374

   Loss related to plant closure


1,543


2,616


   Impairment of intangible assets




80

   Loss (gain) on disposal of assets


12


(14)


(161)

Adjusted EBITDA

$

9,297

$

18,329

$

27,084

 




Nine Months Ended



September 30,

 2014


September 30,

 2013

Net Income

$

15,263

$

20,797

Reconciling items:





   Interest expense


655


1,264

   Income tax provision


8,963


10,911

   Depreciation and amortization


16,072


15,627

   Loss related to plant closure


5,482


                   ―

   Impairment of intangible assets


                   ―


80

   Loss (gain) on disposal of assets


245


213

Adjusted EBITDA

$

46,680

$

48,892

 

Adjusted EBITDA represents net income before interest expense, income tax, depreciation and amortization, loss related to plant closure, impairment of intangible assets and loss (gain) on disposal of assets. The Company has reported Adjusted EBITDA because it believes Adjusted EBITDA is a measure commonly reported and widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted EBITDA assists such investors in comparing a company's performance on a consistent basis. Adjusted EBITDA is not a calculation based on GAAP and should not be considered an alternative to net income in measuring our performance or used as an exclusive measure of cash flow because it does not consider the impact of working capital changes, capital expenditures, debt principal reductions and other sources and uses of cash which are disclosed in our consolidated statements of cash flows. Investors should carefully consider the specific items included in our computation of Adjusted EBITDA. While Adjusted EBITDA has been disclosed herein to permit a more complete comparative analysis of our operating performance relative to other companies, investors should be cautioned that Adjusted EBITDA as reported by us may not be comparable in all instances to Adjusted EBITDA as reported by us or by other companies. Adjusted EBITDA amounts may not be fully available for management's discretionary use, due to certain requirements to conserve funds for capital expenditures, debt service and other commitments, and therefore management relies primarily on our GAAP results. Adjusted EBITDA is not intended to represent net income as defined by GAAP and such information should not be considered as an alternative to net income, cash flow from operations or any other measure of performance prescribed by GAAP in the United States.

Adjusted Net Income and Diluted Earnings Per Share to Net Income Reconciliation
The following table (in thousands, except per share amounts) provides a reconciliation of Adjusted Net Income and Diluted Earnings Per Share, non-GAAP (Generally Accepted Accounting Principles) financial measures, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended September 30, 2014, June 30, 2014 and September 30, 2013 and the nine months ended September 30, 2014 and September 30, 2013:



Three Months Ended



September 30,

 2014


June 30,
2014


September 30,

 2013

Net Income

$

659

$

6,633

$

13,962

Reconciling items:







     Income tax provision prior to adjustments


1,012


3,871


7,377

     Loss related to plant closure


1,543


2,616


               ―

     Impairment of intangible assets


                 ―


                 ―


80

     Loss (gain) on disposal of assets


12


(14)


(161)

Adjusted income before income taxes


3,226


13,106


21,258

     Provision for income taxes after adjustments


1,511


4,830


7,349

Adjusted net income

$

1,715

$

8,276

$

13,909

Adjusted diluted earnings per share

$

0.08

$

0.38

$

0.65

 




Nine Months Ended



September 30,

 2014


September 30,

 2013

Net Income

$

15,263

$

20,797

Reconciling items:





     Income tax provision prior to adjustments


8,963


10,911

     Loss related to plant closure


5,482


               ―

     Impairment of intangible assets


               ―


80

     Loss (gain) on disposal of assets


245


213

Adjusted income before income taxes


29,953


32,001

     Provision for income taxes after adjustments


10,933


11,012

Adjusted net income

$

19,020

$

20,989

Adjusted diluted earnings per share

$

0.88

$

1.00

 

Adjusted net income and Adjusted diluted earnings per share represent net income and diluted earnings per share without loss related to plant closure, impairment of intangible assets, loss (gain) on disposal of assets and taxes associated with these items. The Company has reported Adjusted net income and Adjusted diluted earnings per share because it believes these measures are widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted net income and Adjusted diluted earnings per share assist investors in comparing a company's performance on a consistent basis.  Adjusted net income and Adjusted diluted earnings per share are not calculations based on GAAP and should not be considered alternatives to net income or diluted earnings per share in measuring our performance. Investors should carefully consider the specific items included in our computation of Adjusted net income and Adjusted diluted earnings per share. While Adjusted net income and Adjusted diluted earnings per share has been disclosed herein to permit a more complete comparative analysis of our operating performance across time periods and relative to other companies, investors should be cautioned that these measures as reported by us may not be comparable in all instances to Adjusted net income and Adjusted diluted earnings per share as reported by us or by other companies. Adjusted net income and Adjusted diluted earnings per share are not intended to represent net income or diluted earnings per share as defined by GAAP and such information should not be considered as an alternative to net income, diluted earnings per share or any other measure of performance prescribed by GAAP in the United States .

Logo - http://photos.prnewswire.com/prnh/20120717/NE41641LOGO

SOURCE Omega Protein Corporation

News Provided by Acquire Media